亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

供應(yīng)醋酸氫化可的松,CAS號(hào):50-03-3

 
 
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 湖北武漢市付款后24小時(shí)內(nèi)
型號(hào) 50-03-3
規(guī)格 醫(yī)藥級(jí)
過(guò)期 長(zhǎng)期有效
更新 2011-08-17 16:49
 

湖北康寶泰精細(xì)化工有限公司

企業(yè)會(huì)員第15年
資料未認(rèn)證
保證金未繳納
  • 湖北-武漢市
  • 上次登錄 2011-08-17
  • 湖北康寶泰 (先生)   銷售
詳細(xì)說(shuō)明


醋酸氫化可的松

別名:氫化可的松-21-醋酸酯; 乙酸氫化可的松; 異環(huán)磷酰胺; 氫化可的松醋酸酯; 氫化可的槍乙酸

英文名稱:Hydrocortisone Acetate

CAS號(hào):50-03-3

分子式:C23H32O6

分子量:404.5

外觀:白色或幾乎白色的結(jié)晶性粉末

含量:≥98%

用途:本品為腎上腺皮質(zhì)激素類藥。主要用于治療腎上腺皮質(zhì)功能減退癥的替代治療及先天性腎上腺皮質(zhì)增生癥。有影響糖代謝、抗炎、抗毒、抗休克及抗過(guò)敏等作用。臨床上主要用于治療活動(dòng)性風(fēng)濕病、類風(fēng)濕性關(guān)節(jié)炎、過(guò)敏性及過(guò)敏性結(jié)膜炎等。

包裝:25KG/桶

舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
供應(yīng)美洛昔康,CAS:  71125-38-7 供應(yīng)丙酸氯倍他索,CAS號(hào):25122-46-7 供應(yīng)布地奈德,CAS號(hào): 51333-22-3 供應(yīng)地塞米松 供應(yīng)醋酸曲安奈德 供應(yīng)地索奈德,CAS號(hào):638-94-8 供應(yīng)二丙酸倍他米松,CAS號(hào): 5593-20-4
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |